IOVANCE BIOTHERAPEUTICS, INC.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
IOVA$8.17+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
EXHIBIT INDEX
| | ||
| Exhibit | | Description |
| 3.1 | | Certificate of Incorporation, as amended, of Registrant (incorporated herein by reference to Exhibit 3.1 to Registrant’s Form S-3 filed with the Commission on June 18, 2026). |
| 3.2 | | Fourth Amended and Restated Bylaws of Iovance Biotherapeutics, Inc. (incorporated herein by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K filed with the Commission on March 29, 2024). |
| 10.1++#* | | Separation Agreement and General Release, dated June 8, 2026, by and between Friedrich-Reinhard Graf Finck von Finckensten, M.D., and the Registrant. |
| 10.2++#* | | Consulting Agreement, effective as of June 9, 2026, by and between Friedrich-Reinhard Graf Finck von Finckensten, M.D., and the Registrant. |
| 10.3# | | Iovance Biotherapeutics, Inc. 2020 Employee Stock Purchase Plan, as amended (incorporated herein by reference to Exhibit 99.1 to Registrant’s Form S-8 filed with the Commission on June 18, 2026). |
| 10.4# | | Iovance Biotherapeutics, Inc. Amended and Restated 2021 Inducement Plan, as amended (incorporated herein by reference to Exhibit 99.1 to Registrant’s Form S-8 filed with the Commission on June 18, 2026). |
| 31.1++ | Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer. | |
| 31.2++ | Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer. | |
| 32.1++ | Section 1350 Certification of Chief Executive Officer (furnished herewith). | |
| 32.2++ | Section 1350 Certification of Principal Financial Officer (furnished herewith). | |
| 101.INS++ | | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |
| 101.SCH++ | | Inline XBRL Taxonomy Schema Linkbase Document. |
| 101.CAL++ | | Inline XBRL Taxonomy Calculation Linkbase Document. |
| 101.DEF++ | | Inline XBRL Taxonomy Definition Linkbase Document. |
| 101.LAB++ | | Inline XBRL Taxonomy Labels Linkbase Document. |
| 101.PRE++ | | Inline XBRL Taxonomy Presentation Linkbase Document. |
| 104 | | Cover Page Interactive Data File (the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |
| ++#* | Filed herewith (unless otherwise noted as being furnished herewith).Indicates a management contract or compensatory plan or arrangement.Certain portions of the Exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.